AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today its financial results for the quarter ended March 31, 2007. The results were consistent with the Company’s expectations and guidance. The Company reported progress in both its research and development, manufacturing, clinical and regulatory programs.
